Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme

European Journal of Heart Failure

Volumn 17, Issue 2, 2015, Pages 196-204

  Badar, Athar A ^a,b   Perez Moreno, Ana C ^a   Hawkins, Nathaniel M ^c   Brunton, Alan P T ^a   Jhund, Pardeep S ^a   Wong, Chih M ^a   Solomon, Scott D ^d   Granger, Christopher B ^e   Yusuf, Salim ^f   Pfeffer, Marc A ^d   Swedberg, Karl ^g,h   Gardner, Roy S ^a,b   Petrie, Mark C ^a,b   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Angina; Heart failure

Indexed keywords

AGED; ANGINA PECTORIS; ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FATALITY; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; UNSTABLE ANGINA PECTORIS; CLINICAL TRIAL; COMORBIDITY; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; TETRAZOLE DERIVATIVE;

AGED; ANGINA PECTORIS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; COMORBIDITY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PATIENT OUTCOME ASSESSMENT; STROKE VOLUME; TETRAZOLES;

EID: 84922948724     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.221     Document Type: Article

References (20)

1. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006; 114: 1202-1213.
2. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
3. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
4. Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013; 15: 1173-1184.
5. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J, Gras D, Krum H, Sogaard P, Holzmeister J. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369: 1395-1405.
6. Badar AA, Perez-Moreno AC, Jhund P, Chong CM, Hawkins NM, Cleland JGF, Veldhuisen DJF, Wikstrand J, Kjekshus J, Wedel H, Watkins S, Gardner RS, Petrie MC, McMurray JJV. Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2014; 35: 3426-3433.
7. Mentz RJ, Broderick S, Shaw LK, Fiuzat M, O'Connor CM. Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease). J Am Coll Cardiol 2014; 63: 251-258.
8. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.
9. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail 1999; 5: 276-282.
10. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392.
11. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005; 11: 576-585.
12. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJV, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27: 65-75.
13. Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, Calvin JE. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 2002; 112: 437-445.
14. Brophy JM, Dagenais GR, McSherry F, Williford W, Yusuf S. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med 2004; 116: 300-304.
15. Liao L, Jollis JG, Anstrom KJ, Whellan DJ, Kitzman DW, Aurigemma GP, Mark DB, Schulman KA, Gottdiener JS. Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med 2006; 166: 112-118.
16. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
17. Mentz RJ, Fiuzat M, Shaw LK, Phillips HR, Borges-Neto S, Felker GM, O'Connor CM. Comparison of clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease). Am J Cardiol 2012; 109: 1272-1277.
18. Ahmed A, Zile MR, Rich MW, Fleg JL, Adams KFJ, Love TE, Young JB, Aronow WS, Kitzman DW, Gheorghiade M, Dell'Italia LJ. Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol 2007; 99: 460-464.
19. Ekman I, Cleland JGF, Swedberg K, Charlesworth A, Metra M, Poole-Wilson PA. Symptoms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail 2005; 11: 288-292.
20. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002; 39: 210-218.